Echosens Achieves Critical FDA Acceptance for FibroScan®
This significant achievement opens avenues for FibroScan® to replace traditional liver biopsy in clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) drug development.
Today, Echosens, a leader in non-invasive liver diagnostics, announced that the U.S. Food and Drug Administration (FDA) has acknowledged its Letter of Intent for qualifying Liver Stiffness Measurement by Vibration-Controlled Transient Elastography (FibroScan®). This step marks the FDA's first acceptance of a non-invasive test as a reasonable surrogate endpoint in clinical trials focused on MASH.
MASH is a complex liver disease characterized by fat accumulation that can progress to severe complications, including cirrhosis and liver cancer. The FDA has indicated through a communication provided by Frank Anania, MD, that this qualification represents a substantial advancement in non-invasive testing for MASH-related drug development.
The Letter of Intent states that LSM using FibroScan® precisely predicts risks of various liver-related events in MASH patients. With acceptance of this letter, FibroScan® is on course to replace liver biopsies as a primary measure in interim analyses for drugs seeking accelerated approval for adults suffering from non-cirrhotic MASH.
The transition from invasive liver biopsies, essential for both patient recruitment and monitoring treatment efficacy, to FibroScan® presents a significant relief for those affected. This non-invasive procedure, which takes only a few minutes and causes no discomfort, offers a comprehensive evaluation of liver health that can be safely repeated as necessary.
Expert Insights on FDA Acceptance
Dr. Arun Sanyal, a leading expert in liver disease at the Stravitz-Sanyal Institute, commented on the importance of this milestone. He emphasized that years of clinical research and collaborative efforts have culminated in this significant FDA development, which is expected to enhance drug development in a way that is easily integrated into clinical practices.
This momentous acceptance by the FDA is underpinned by the outstanding clinical validation of FibroScan® and its prominence in pivotal pharmaceutical trials centered on liver diseases. With the backing of over 5,600 citations in peer-reviewed literature, FibroScan® is recognized globally as a premier non-invasive option for assessing liver health.
Pharmaceutical stakeholders have also endorsed the use of FibroScan® in their research efforts for MASH therapies. Echosens' submission to the FDA included letters of support from major companies, highlighting widespread backing for this innovative approach.
Implications for Drug Development
The acceptance of FibroScan® as a surrogate endpoint is poised to revolutionize the way drugs are developed for MASH. This breakthrough could greatly streamline patient recruitment and retention in clinical trials while helping researchers design more effective and safe trial methodologies.
Professor Quentin Anstee from Newcastle University emphasized that this FDA decision signals pharmaceutical sponsors to prioritize robust non-invasive data collection in their ongoing and future studies related to MASH.
In addition to existing endorsements in prominent healthcare guidelines and payer policies, FDA acceptance further solidifies FibroScan®'s role as a primary non-invasive tool for prescribing and monitoring MASH treatments, paving the way for both existing and emerging therapeutic options.
Technological Advancements by Echosens
Recently, Echosens further enhanced its technology, notably with the introduction of Guided VCTE in its latest FibroScan® devices. These advancements aim to improve the efficiency and standardization of liver assessments, thereby simplifying the process for healthcare providers engaged in liver health management.
About Echosens
Echosens is a pioneer in transforming liver assessment practices with its FibroScan® technology. This innovative, non-invasive solution has made a global impact, boasting validation through over 5,600 peer-reviewed publications and nearly 220 international clinical guidelines. Implemented across more than 127 countries, FibroScan® has enabled millions of liver exams worldwide.
Frequently Asked Questions
What is FibroScan® used for?
FibroScan® is a non-invasive diagnostic tool that assesses liver stiffness, helping to manage liver health and diseases, particularly MASH.
What does the FDA's acceptance mean for Echosens?
This acceptance signifies a key milestone for Echosens, validating FibroScan® as a promising surrogate endpoint and potentially facilitating faster drug development for MASH.
How does FibroScan® compare to traditional liver biopsies?
Unlike traditional liver biopsies, FibroScan® is painless, quick, and can be performed multiple times without the risks associated with invasive procedures.
What is MASH?
MASH, or metabolic dysfunction-associated steatohepatitis, is a severe form of fatty liver disease that can lead to significant complications, including cirrhosis and liver cancer.
What innovations has Echosens introduced recently?
Echosens has developed Guided VCTE technology in its latest FibroScan® devices, which enhances the efficiency and consistency of liver assessments for better patient outcomes.
